The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $15.65

Today's change-0.15 -0.95%
Updated June 23 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $15.65

Today's change-0.15 -0.95%
Updated June 23 4:00 PM -4GMT. Delayed by at least 15 minutes.

Coherus BioSciences Inc down (U.S.)$0.15

Coherus BioSciences Inc closed lower Friday, dropping (U.S.)$0.15 or 0.95% to (U.S.)$15.65. Over the last five days, shares have gained 5.39%, but are down 44.40% for the last year to date. Shares have underperformed the S&P 500 by 20.36% during the last year.

Key company metrics

  • Open(U.S.) $15.90
  • Previous close(U.S.) $15.80
  • High(U.S.) $16.08
  • Low(U.S.) $15.55
  • Bid / Ask(U.S.) $15.10 / (U.S.) $15.80
  • YTD % change-44.40%
  • Volume1,118,029
  • Average volume (10-day)1,640,929
  • Average volume (1-month)1,087,510
  • Average volume (3-month)681,585
  • 52-week range(U.S.) $14.00 to (U.S.) $31.98
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.34
Updated June 23 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.65%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue0116314
Total other revenue--------
Total revenue0116314
Gross profit--------
Total cost of revenue--------
Total operating expense73747877
Selling / general / administrative19151411
Research & development54596566
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-72-7385-63
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-75-7684-70
Income after tax-75-7684-70
Income tax, total--------
Net income-75-7684-70
Total adjustments to net income--------
Net income before extra. items-75-7684-70
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-75-7684-70
Inc. avail. to common incl. extra. items-75-7684-70
Diluted net income-75-7684-70
Dilution adjustment----0--
Diluted weighted average shares49445241
Diluted EPS excluding extraordinary itemsvalue per share-1.54-1.711.63-1.72
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-1.54-1.711.63-1.72